Predictive variables of palbociclib dose reduction and its impact on survival outcomes: A retrospective bicentric study

Breast J. 2021 Apr;27(4):415-416. doi: 10.1111/tbj.14195. Epub 2021 Feb 14.

Authors

Francesca Rita Ogliari¹, Francesca Caspani¹, Lorenzo Rossi², Marta Nerone², Ilaria Vallini¹, Rossana Gueli¹

Affiliations

¹ Department of Medical Oncology, ASST-Settelaghi, Circolo Hospital, Varese, Italy.
² Department of Medical Oncology, Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland.

PMID: 33586266
DOI: 10.1111/tbj.14195

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms*
Drug Tapering*
Female
Humans
Piperazines
Pyridines
Receptor, ErbB-2
Retrospective Studies

Substances

Piperazines
Pyridines
Receptor, ErbB-2
palbociclib